

## Enanta Pharmaceuticals Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 03-Mar-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

# Enanta Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	Enanta Pharmaceuticals Inc
Parent Company Name	Enanta Pharmaceuticals Inc
Website	http://www.enanta.com/
Country	US
Number of Drugs in Active Development	10
Number of Inactive Drugs	3
Number of Patents as Owner	153
Number of Patents as Third Party	0
Number of Deals	5
Key Indications	Hepatitis C virus infection,Bacterial infection,MRSA infection,Gram positive bacterium infection,Bacterial respiratory tract infection,Hepatitis B virus infection,Inflammatory disease,Neisseria gonorrhoeae infection,HIV infection,Cystic fibrosis
Key Target-based Actions	Hepatitis C virus NS3 protease inhibitor,Hepatitis C virus NS5B polymerase inhibitor,Hepatitis C virus protein NS5A inhibitor,Peptidylprolyl isomerase inhibitor,Flavivirus NS3 protease inhibitor,Hepatitis C virus NS2-NS3 protease inhibitor,Hepatitis C virus protease inhibitor
Key Technologies	Small molecule therapeutic,Antibiotic,Oral formulation,Prodrug,Intravenous formulation,Dermatological formulation,Inhalant formulation,Local formulation unspecified,Systemic formulation unspecified,Chemical intermediate,Peptide

## COMPANY PROFILE

### SUMMARY

Enanta Pharmaceuticals is a drug discovery company specializing in the development of small molecule anti-infective agents, especially macrolide and ketolide antibiotics.

### LICENSING AGREEMENTS

In March 2003, Enanta received a milestone payment from Chiron for the completion of the first phase of Enanta's research for the discovery and development of small molecule HCV therapeutics. In September 2002, Enanta signed an exclusive, joint collaboration with Chiron for the discovery and development of small molecule HCV therapeutics. Enanta was to apply its macrocyclic chemistry and medicinal chemistry expertise to design and synthesize compounds targeting enzymes involved in the replication of the virus. Chiron gave Enanta a non-exclusive license to its HCV patents and Enanta gave Chiron an exclusive worldwide license to compounds that were developed. Enanta was also to receive research funding, milestone payments and royalties, while Chiron was to be responsible for preclinical and clinical development, manufacturing and sales and marketing.

### FINANCIAL

In November 2012, Enanta filed a registration statement with the U.S. Securities and Exchange Commission for proposed initial public offering of its common stock.

In August 2004, Enanta raised \$20 million in new financing, including contributions from Shionogi & Co Ltd, in order to advance its bridged bicyclic ketolide, EP-013420, into phase I trials, and to progress the company's discovery-stage anti-infective programs.

In January 2004, Enanta raised \$12 million in financing to advance its lead macrolide antibiotic program into clinical trials.

In June 2002, raised \$18 million in a private financing.

In 1999, Enanta raised \$5.1 million of equity financing and in July 2000, received \$20 million in a second round of private financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	10	2	12
Gastrointestinal disease	4	2	6
Inflammatory disease	4	2	6
Respiratory disease	1	2	3
Immune disorder	0	1	1
Dermatological disease	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	8
Suspended	1
Discontinued	2
No Development Reported	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	1	0	0	0	1
Drug - Development/Commercialization License	3	0	1	0	4

[Return to Table of Contents](#)

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	0	8
Respiratory disease	0	4
Dermatological disease	0	1
Gastrointestinal disease	0	1
Inflammatory disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	3
Phase 1	0	5

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	3	0	3
Endocrine disease	2	0	2
Gastrointestinal disease	113	0	113
Genitourinary disease	1	0	1
Growth disorder	2	0	2
Degeneration	2	0	2
Immune disorder	14	0	14
Musculoskeletal disease	9	0	9
Neoplasm	4	0	4
Ocular disease	3	0	3

[Return to Table of Contents](#)





Metabolic disorder	3	0	3
Mouth disease	2	0	2
Neurological disease	2	0	2
Respiratory disease	38	0	38
Infectious disease	144	0	144
Inflammatory disease	116	0	116
Otorhinolaryngological disease	8	0	8
Gynecology and obstetrics	2	0	2
Temperature disorder	1	0	1
Dermatological disease	11	0	11
Ulcer	2	0	2
Surgical procedure	3	0	3

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### ABT-450

<b>Drug Name</b>	ABT-450
<b>Key Synonyms</b>	
<b>Originator Company</b>	Chiron Corp
<b>Active Companies</b>	AbbVie Inc, Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	Abbott Laboratories, Chiron Corp
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Hepatitis C virus NS3 protease inhibitor
<b>Other Actions</b>	Hepatitis C virus replication inhibitor
<b>Technologies</b>	Oral formulation, Capsule formulation, Tablet formulation, Small molecule therapeutic
<b>Last Change Date</b>	04-Jan-2013

### modithromycin

<b>Drug Name</b>	modithromycin
<b>Key Synonyms</b>	modithromycin
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	Shionogi & Co Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Neisseria gonorrhoeae infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Macrolide antibiotic
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	18-Sep-2012

[Return to Table of Contents](#)

### EDP-MRSA-1 (intravenous), Enanta

<b>Drug Name</b>	EDP-MRSA-1 (intravenous), Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	MRSA infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Macrolide antibiotic
<b>Technologies</b>	Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	04-Feb-2012

### HCV polymerase inhibitors, Enanta

<b>Drug Name</b>	HCV polymerase inhibitors, Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Hepatitis C virus NS5B polymerase inhibitor
<b>Other Actions</b>	
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	26-Apr-2012

[Return to Table of Contents](#)

### HCV cyclophilin binders/replication inhibitors, Enanta

<b>Drug Name</b>	HCV cyclophilin binders/replication inhibitors, Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Peptidylprolyl isomerase inhibitor
<b>Other Actions</b>	Hepatitis C virus replication inhibitor
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	12-Feb-2013

### bicyclolide antibiotics (respiratory tract infection), Enanta

<b>Drug Name</b>	bicyclolide antibiotics (respiratory tract infection), Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Bacterial respiratory tract infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Macrolide antibiotic
<b>Technologies</b>	Antibiotic, Small molecule therapeutic
<b>Last Change Date</b>	31-Oct-2012

[Return to Table of Contents](#)

### EDP-788 (oral prodrug, bacterial infections), Enanta

Drug Name	EDP-788 (oral prodrug, bacterial infections), Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Prodrug, Oral formulation, Antibiotic, Small molecule therapeutic
Last Change Date	08-Feb-2013

### EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals

Drug Name	EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Prodrug, Intravenous formulation, Antibiotic, Small molecule therapeutic
Last Change Date	12-Feb-2013

[Return to Table of Contents](#)

## NS5B nucleotide polymerase inhibitors (HCV infection), Enanta

<b>Drug Name</b>	NS5B nucleotide polymerase inhibitors (HCV infection), Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Hepatitis C virus NS5B polymerase inhibitor
<b>Other Actions</b>	
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	08-Feb-2013

## EDP-322

<b>Drug Name</b>	EDP-322
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Suspended
<b>Active Indications</b>	Gram positive bacterium infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Macrolide antibiotic
<b>Technologies</b>	Oral formulation, Antibiotic, Small molecule therapeutic
<b>Last Change Date</b>	31-Oct-2012

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

